Evidence mapPaperPMID 42535626Full record

ReviewChemical biology & drug design2026

Integrating Artificial Intelligence Into Drug Discovery From Medicinal Plants: Current Applications and Infrastructural Challenges.

Amit Gangwal, Azim Ansari, Mohd Usman Mohd Siddique, Jyotiram Sawale, Suhas Padmane, Raju Wadekar

Abstract readReview
In one paragraph

Review in Chemical biology & drug design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Amit GangwalDepartment of Pharmacognosy, SVKM NMIMS Global University School of Pharmacy and Technology Management, Dhule, Maharashtra, India.ORCID https://orcid.org/0000-0003-3228-5437
Azim AnsariDepartment of Pharmaceutical Chemistry, SVKM NMIMS Global University School of Pharmacy and Technology Management, Dhule, Maharashtra, India.ORCID https://orcid.org/0000-0003-1757-9437
Mohd Usman Mohd SiddiqueDepartment of Pharmaceutical Chemistry, SVKM NMIMS Global University School of Pharmacy and Technology Management, Dhule, Maharashtra, India.ORCID https://orcid.org/0000-0001-9503-1771
Jyotiram SawaleDepartment of Pharmacognosy, Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, Maharashtra, India.ORCID https://orcid.org/0000-0002-8383-7249
Suhas PadmaneDepartment of Pharmaceutical Quality Assurance, Gurunanak College of Pharmacy, Nagpur, India.ORCID https://orcid.org/0009-0006-6768-5157
Raju WadekarDepartment of Pharmacognosy, SVKM NMIMS Global University School of Pharmacy and Technology Management, Dhule, Maharashtra, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medicinal plants represent a vast and evolutionarily refined reservoir of structurally diverse bioactive compounds that have historically contributed to major therapeutic breakthroughs. However, despite their pharmacological richness, systematic translation of plant-derived metabolites into clinically approved drugs remains constrained by persistent bottlenecks, including extract complexity, dereplication redundancy, structural elucidation challenges, taxonomic ambiguity, and multi-component pharmacology. This review presents a bottleneck-driven and systems-oriented framework for integrating artificial intelligence (AI) into medicinal plant-based drug discovery (MPDD) to address some of these bottlenecks. Rather than reiterating broadly documented AI tools used in synthetic drug development, the manuscript critically examines phytomedicine-specific challenges and maps AI applications across key stages of the pipeline: medicinal plant identification, extraction optimization, plant metabolite identification and dereplication, absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction, virtual screening, network pharmacology, repurposing, and generative de novo design of pseudo-natural products. Emphasis is placed on the foundational requirement of making phytochemical datasets truly AI-ready through metadata harmonization, dataset balancing, novelty-aware modeling, and structured data engineering. Emerging approaches such as transformer-based foundational models, graph neural networks (GNNs), generative AI (GAI) architectures, and multi-omics-integrated network pharmacology are discussed within a pragmatic translational context. Importantly, this review maintains a balanced perspective, acknowledging that fully AI-driven clinically approved botanical drugs/synthetic drugs have yet to emerge and identifies challenges limiting the progress. By integrating computational methods with infrastructural reform, this work outlines a progressive roadmap to transition AI in medicinal plant research from exploratory studies toward standardized, reproducible, and biologically grounded next-generation drug discovery.

Indexed as

Artificial IntelligenceDrug DiscoveryPlants, MedicinalBiological ProductsHumansBiological ProductsADMETartificial intelligencedereplicationdrug discoverydrug repurposinggenerative AImachine learningmedicinal plantsnetwork pharmacologyvirtual screening

Identifiers

PMID42535626
PMCPMC13425709

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.